Persbericht Innovatieve reuma-scanner gaat internationaal 28 augustus 2017 (Dutch)
Medtech startup Hemics verkoopt eerste HandScan-systemen over de grens
De Nederlandse medisch-technologische innovatie ‘HandScan’ wordt deze maand voor het eerst in het buitenland in gebruik genomen. Klinieken in Duitsland en België hebben de innovatieve reuma-scanner van de Eindhovense start-up Hemics aangeschaft. Voor Hemics is dit een belangrijke stap naar haar doel, om ook internationaal een verschil te maken in het leven van veel reumatoïde artritis (RA-) patiënten.
Press release Dutch innovative rheumatism scanner on the rise August 28, 2017
Medtech start-up Hemics sells first HandScan systems internationally
The HandScan, a Dutch medical technology innovation, will be used this month for the first time outside the Netherlands. Clinics in Germany and Belgium have purchased the innovative rheumatism scanner from Eindhoven start-up company Hemics. This marks an important step for Hemics towards its goal of making a difference internationally as well as nationally in the life of many patients who suffer from rheumatoid arthritis (RA).
Press release Máxima Medisch Centrum January 10, 2017 (Dutch)
MMC biedt als allereerste pijnloze controle voor artritispatiënten
Reumatoïde artritispatiënten worden vanaf nu pijnloos onderzocht op ontstekingen dankzij een HandScan. De objectieve metingen van dit apparaat kunnen bovendien leiden tot een betere bijstelling van vaak kostbare medicatie. Máxima Medisch Centrum (MMC) neemt de HandScan als eerste ziekenhuis ter wereld in gebruik in de dagelijkse praktijk.
Press release September 16, 2015
Pan-European APPROACH project receives 15 million Euro research funding to find the right osteoarthritis medicine for the right patient
In a bid to stimulate the development of much needed treatments for osteoarthritis, a consortium of 24 partners comprising pharmaceutical companies, biotech companies, academic institutions, not-for-profit organizations, small and medium enterprises (SMEs) and public bodies have joined forces in the pan-European APPROACH (Applied Public-Private Research enabling OsteoArthritis Clinical Headway) project, with total research funding of 15 million Euros. Of this amount, 7.5 million Euros will come from the European Innovative Medicines Initiative (IMI) and 7.5 million Euros in the form of ‘in kind’ contributions from participating members of the European Federation of Pharmaceutical Industries and Associations (EFPIA).
Press release January 9, 2015
Hemics receives required CE marking and closes B-round financing to market the HandScan
Hemics BV received CE marking required for commercial sales of its medical device the HandScan and closed a new investment round, welcoming new investor DFZ Participaties, a subsidiary of health insurance company De Friesland. Existing investors Thuja Capital, Point One Innovation Fund, and the Brabant Development Agency (BOM) also participated. The investment will enable Hemics to further develop, clinically test and market the HandScan, an optical imaging device to monitor joint inflammation in hands and wrists of Rheumatoid Arthritis (RA) patients.
Persbericht 9 januari 2015
Hemics verkrijgt vereiste CE markering en sluit serie B-financieringsronde om de HandScan te vermarkten
Hemics BV heeft CE markering verkregen, vereist voor commerciële verkoop van haar medisch product de HandScan, en heeft haar tweede financieringsronde succesvol afgerond. Nieuw toegetreden is DFZ Participaties, een dochter van De Friesland Zorgverzekeraar. Bestaande investeerders Thuja Capital, Point One Innovation Fund en de Brabantse Ontwikkelings Maatschappij (BOM) hebben ook deelgenomen aan de B-ronde. Hemics gaat de investering gebruiken voor verdere ontwikkeling, klinische studies, en het naar de markt brengen van de HandScan, een optisch beeldvormend apparaat om ontsteking in hand- en polsgewrichten te visualiseren bij patienten met reumatoïde artritis.
News, October 10, 2014
Hemics awarded a H2020 SME instrument subsidy
Hemics received a H2020 SME instrument subsidy from the European commission for initial concept and feasibility assessment of a scanner to visualize inflammation in joints in the feet. The foot scanner idea builds on the HandScan technology which Hemics has developed to visualize inflammation in the joints of hands and wrists to support rheumatologists in their treatment decisions. In total 155 (out of 2666) proposals from 21 countries were granted funding (see list here). From the Netherlands 108 proposals were submitted of which 4 were awarded subsidy.
News, October 10, 2014
HandScan finalist for Accenture Innovation Awards
The HandScan is one of five finalists competing for the High Tech Accenture Innovation Awards 2014. More information about the Awards can be found here.
News, September 10, 2014
Hemics completes ISO 13485 certification
Hemics has received the International Organization for Standardization (ISO) 13485:2003 certificate from SGS United Kingdom. This certification bestows official recognition on the company for its quality management system governing the design, manufacturing, installation and service of medical devices.
Press Release March 31, 2014
Cost effectiveness and efficacy of the Hemics HandScan will be studied in multi-center tight control treatment of Rheumatoid Arthritis.
Hemics BV announces today a multi-center clinical study to evaluate the cost effectiveness and efficacy of its HandScan in tight control treatment of Rheumatoid Arthritis (RA). The study will be performed at the University Medical Center (UMC) Utrecht and four general hospitals in the same region, partners of the SRU (Stichting Reumaonderzoek Utrecht), in collaboration with the Dutch Arthritis Foundation and Hemics. In an earlier study in UMC Utrecht using Ultrasound (US) measurements as gold standard, a prototype of the HandScan showed superior performance in detecting joint inflammation when compared to clinical examination, suggesting that HandScan is a better tool for monitoring rheumatoid arthritis. The present study will determine whether this is indeed the case.
Persbericht 31 maart 2014
Ontsteking pijnloos meten met licht: Groot Nederlands onderzoek naar betere controle reuma
Binnenkort start een Nederlandse studie waarin de kosteneffectiviteit en doeltreffendheid wordt onderzocht van de HandScan, een optisch apparaat waarmee het verloop van reumatoïde artritis mogelijk beter kan worden gevolgd.
News February 4, 2014
Hemics shows HandScan at three rheumatology conferences in 2014
Hemics will exhibit its HandScan at the European rheumatology conference (EULAR) in Paris in June 2014 at booth no. P24. In September the company will exhibit at the German rheumatology meeting (DGRh) in Düsseldorf and the Dutch rheumatology meeting (NVR) in Arnhem. News June 24, 2013. Hemics gives sneak previews of its HandScan at EULAR in Madrid, DGRh Conference in Mannheim and the NVR Conference in Arnhem, the Netherlands. Hemics exhibited for the first time at the European rheumatology conference (EULAR), which was held in Madrid earlier this month. The company gave a preview of its HandScan which the company expects to launch into the European market in 2014. At the same conference clinical collaborators presented the results of an observational study with an earlier prototype (van Onna et al., Ann Rheum Dis, 2013; 72, suppl3). In September the company will show the HandScan at the German rheumatology meeting (DGRh)and the Dutch rheumatology meeting (NVR).
Press release April 22, 2013
Hemics and DEMCON start HandScan development, the first non-invasive imaging system for monitoring inflammatory status of Rheumatoid Arthritis patients
Hemics BV and Demcon Advanced Mechatronics BV announce that they have started developing the HandScan into a commercial product. This non-invasive imaging system was developed by Hemics for monitoring the inflammatory status of Rheumatoid Arthritis (“RA”) patients. As part of the collaboration, DEMCON will be responsible for systems engineering, electronics, mechanics, optics and embedded software, while Hemics will remain in charge of the data algorithm, which translates the measurement results from the scanner into clinical information for rheumatologists. The two partners are facing the challenge of designing a lightweight, compact, easy-to-use and affordable device. Given that rheumatologists have to accept the device as part of their daily work, it is not only the illumination module that requires special attention, but the intuitive user interface and the industrial design as well.
Press release April 5, 2013
Akeso Medical Imaging renamed Hemics.
Akeso Medical Imaging BV announces today that as of this day the company has adopted a new name: Hemics BV. Hemics is the first company in the world to develop a non invasive optical imaging device that supports the rheumatologist in objective assessment of inflammatory status in RA. Inflammatory status is a key parameter for rheumatologists in treatment decisions for patients with RA. Reducing the inflammation to a state of remission will improve quality of life of RA patients and reduce long term disability. The device works by measuring the blood flow in 22 joints of the hands and wrists using diffuse optical transmission in combination with a patented blood flow modulation method. Based on optical technology the device poses no risk for the patient and is fast, operator independent, inexpensive and easy to use.
Press Release March 1, 2012
Akeso Medical Imaging starts clinical study for proof of concept of imaging device for rheumatoid arthritis disease activity monitoring and control.
Akeso Medical Imaging BV, announces today the start of a clinical study with their novel imaging device for assessment of joint inflammation in patient with rheumatoid arthritis (RA). In this proof of concept study, Akeso’s imaging device will be compared to other methods to assess disease status, such as the DAS-28 score, Ultrasound and in some cases MRI. The study will be performed at the University Medical Center Utrecht (UMC Utrecht) in cooperation with Regional Rheumatology Centre Eindhoven (RRC). Seventy subjects will be included; sixty RA patients with varying degrees of inflammation of the joints of hands and wrists at the time of examination and a control group of ten subjects.
News February 22, 2012
Appointment of new Supervisory Board Members at Akeso Medical Imaging.
The general meeting of shareholders of Akeso Medical Imaging BV has decided to appoint three new members to the Supervisory Board. As of today the Supervisory Board consists of dr. Harrold van Barlingen (chairman), dr. Theo Claassen, and the new board members Mr. Rob Lips, dr. Rob Slobbe and Mr. Jack van Sprang. The new board members bring a rich experience in international healthcare business development, quality and regulatory affairs and medical device development. More information about the supervisory board can be found here.
News December 14, 2011
Akeso Medical Imaging receives Innovation Credit by Dutch Government for development of Rheumatoid Arthritis imaging system.
Akeso Medical Imaging has received an innovation credit of more than 850.000 euro from AgentschapNL, a subsidiary of the Dutch Ministry of Economic Affairs, Agriculture and Innovation, to support the development of its imaging device for rheumatoid arthritis disease activity monitoring and control. The credit will support the company’s proof of concept tests and further development of the imaging system and software. Petra van den Elsen, CEO at Akeso comments: "We are delighted to receive this innovation credit; it is an acknowledgement of the innovative character of our imaging device and the potential for commercial success, both prerequisites to qualify for the innovation credit."
Press Release September 20, 2011
Akeso Medical Imaging closes its first financing round to develop an imaging device for rheumatoid arthritis disease activity monitoring and control.
Akeso Medical Imaging BV, a spin-off from Philips Research, announces today the closure of its first financing round led by Thuja Capital Healthcare Seed Fund with additional financing from the Brabant Spin-Off Fund and Point-One Innovation Fund. Philips will be a minority shareholder of Akeso Medical Imaging as a result of its contribution to the development of Akeso’s innovative Rheumatoid Arthritis (RA) imaging system. The funds will be used to further develop the imaging system and software, its clinical validation and for obtaining regulatory approval in Europe.